Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Melevodopa→

Melevodopa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7101-51-1
Molecular formula
C10H13NO4
Molecular weight
211.21 g/mol
Drug class
Levodopa prodrugmethyl ester of L-DOPA
Mechanism of action
Melevodopa is the methyl ester of levodopa. Following hydrolysis to levodopa, it enters the brain via amino-acid transport and is decarboxylated by aromatic L-amino-acid decarboxylase to dopamine, replenishing deficient striatal dopaminergic signalling.
Indications / reported uses
  • Investigated and used in some countries as a rapidly absorbed levodopa form for treatment of Parkinson’s disease, generally in combination with a peripheral dopa-decarboxylase inhibitor. Product availability and authorisation are jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/23497 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/levodopa · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Melevodopa Environmental Risk Assessment (ERA) (the Melevodopa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.